Xtandi meets in Phase III for non-metastatic CRPC

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) reported top-line data from the Phase III PROSPER trial in about 1,400 patients with non-metastatic castration-resistant prostate cancer (CRPC) showing that once-daily 160 mg oral Xtandi enzalutamide plus androgen deprivation therapy met the primary endpoint of improving metastasis-free survival (MFS) compared to androgen deprivation therapy alone.

The partners did not release specific data, but plan to submit the results for presentation at an upcoming medical meeting. The companies plan to discuss the data with global health authorities to potentially support expanding Xtandi's label to include all CRPC patients. The oral androgen receptor antagonist is already approved to treat metastatic CRPC...